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SUMMARY
Thiamine monophosphatase (TMPase, also known as Fluoride-Resistant Acid Phosphatase) is a
classic histochemical marker of small-diameter dorsal root ganglia neurons. The molecular identity
of TMPase is currently unknown. We found that TMPase is identical to the transmembrane isoform
of Prostatic Acid Phosphatase (PAP), an enzyme with unknown molecular and physiological
functions. We then found that PAP knockout mice have normal acute pain sensitivity but enhanced
sensitivity in chronic inflammatory and neuropathic pain models. In gain-of-function studies,
intraspinal injection of PAP protein has potent anti-nociceptive, anti-hyperalgesic and anti-allodynic
effects that last longer than the opioid analgesic morphine. PAP suppresses pain by functioning as
an ecto-5’-nucleotidase. Specifically, PAP dephosphorylates extracellular adenosine monophosphate
(AMP) to adenosine and activates A1-adenosine receptors in dorsal spinal cord. Our studies reveal
molecular and physiological functions for PAP in purine nucleotide metabolism and nociception and
suggest a novel use for PAP in the treatment of chronic pain.
INTRODUCTION
Painful and tissue-damaging stimuli are sensed by small-diameter nociceptive neurons, located
in the dorsal root ganglia (DRG) and trigeminal ganglia (Woolf and Ma, 2007). For nearly fifty
years, it was known that many small-diameter DRG neurons expressed a histochemically
identifiable acid phosphatase (Colmant, 1959), commonly referred to as Fluoride-Resistant
Acid Phosphatase (FRAP) or Thiamine Monophosphatase (TMPase) (Dodd et al., 1983;
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Knyihar-Csillik et al., 1986). TMPase dephosphorylates diverse substrates, including the
Vitamin B1 derivative thiamine monophosphate (TMP) and 5’-nucleotide monophosphates
(Dodd et al., 1983; Sanyal and Rustioni, 1974; Silverman and Kruger, 1988a).
TMPase was intensively studied in the 1980s in an effort to determine its molecular identity
and function. TMPase marks most nonpeptidergic DRG neurons, a subset of peptidergic DRG
neurons and unmyelinated axon terminals in lamina II of the dorsal spinal cord (Carr et al.,
1990; Dalsgaard et al., 1984; Dodd et al., 1983; Hunt and Rossi, 1985; Knyihar-Csillik et al.,
1986; Nagy and Hunt, 1982; Silverman and Kruger, 1988a). Since peptidergic and
nonpeptidergic neurons are generally considered to be nociceptive (Woolf and Ma, 2007), these
anatomical studies suggested TMPase might function in nociception. Moreover, TMPase
staining in lamina II of spinal cord is reduced or eliminated when peripheral nerves are damaged
(Colmant, 1959; Csillik and Knyihar-Csillik, 1986; Shields et al., 2003; Tenser, 1985; Tenser
et al., 1991). Ultimately, studies of TMPase waned when it was found that isolectin B4 (IB4)
co-localized with TMPase and was an easier-to-use marker of nonpeptidergic neurons
(Silverman and Kruger, 1988b; Silverman and Kruger, 1990). More importantly, the gene
encoding TMPase was never identified, making it impossible to study the molecular and
physiological function of TMPase in sensory neurons.
In an attempt to identify the TMPase gene, Dodd and co-workers partially purified TMPase
protein from rat DRG using chromatography (Dodd et al., 1983). The partially purified rat
protein was inhibited by the non-selective acid phosphatase inhibitor L(+)-tartrate and was
similar in molecular weight to the secretory isoform of human prostatic acid phosphatase (PAP,
also known as ACPP), the only known isoform of PAP at the time (Ostrowski and Kuciel,
1994). These biochemical experiments hinted that TMPase might be secretory PAP (Dodd et
al., 1983). However, subsequent studies using anti-PAP antibodies failed to immunostain
small-diameter DRG neurons and their axon terminals in lamina II (i.e. the neurons and axons
that contain TMPase) (Dodd et al., 1983; Silverman and Kruger, 1988a). As summarized by
Silverman and Kruger in 1988, these data made it impossible to determine if TMPase was PAP
or some other enzyme.
In light of this unsolved question regarding the molecular nature of TMPase and the historical
use of TMPase as a nociceptive neuron marker, we sought to definitively identify the TMPase
gene and ascertain its function in nociception. Our experiments revealed that TMPase was a
recently-discovered transmembrane (TM) isoform of PAP (TM-PAP) (Quintero et al., 2007)
and was not the secretory isoform of PAP. This molecular identification then allowed us to use
modern molecular and genetic approaches to rigorously study the function of PAP/TMPase in
nociceptive circuits. Using our PAP knockout mice, we found that deletion of PAP increased
thermal hyperalgesia (increased pain sensitivity) and mechanical allodynia in animal models
of chronic pain. Conversely, a single intraspinal injection of PAP protein had anti-nociceptive,
anti-hyperalgesic and anti-allodynic effects that lasted for up to three days, much longer than
a single injection of the commonly used opioid analgesic morphine. Mechanistically, we found
that PAP is an ectonucleotidase that dephosphorylates extracellular AMP to adenosine and
requires A1-adenosine receptors (A1Rs) for anti-nociception.
PAP has been intensively studied for seventy years in the prostate cancer field (Gutman and
Gutman, 1938). Despite decades of research, the molecular and physiological functions for
PAP remained unknown. Our studies with pain-sensing neurons are the first to identify the in
vivo substrate, the molecular mechanism and the physiological function for this medically-
relevant protein. Moreover, we are the first to show that PAP functions in nociception.
Considering that TM-PAP is expressed throughout the body (Quintero et al., 2007), PAP could
regulate diverse physiological processes that are dependent on adenosine (Jacobson and Gao,
2006).
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Prostatic acid phosphatase is TMPase in dorsal root ganglia sensory neurons
In rats, mice and humans, PAP is expressed as a secreted protein or as a type 1 transmembrane
(TM) protein, with the catalytic acid phosphatase domain localized extracellularly (Figure 1A)
(Quintero et al., 2007; Roiko et al., 1990; Vihko, 1979). The secretory isoform has been used
as a diagnostic marker for prostate cancer for nearly seventy years whereas the TM isoform
was only recently discovered (Gutman and Gutman, 1938; Quintero et al., 2007). To determine
if either PAP isoform is expressed in DRG, we performed in situ hybridization with isoform-
specific antisense riboprobes. These experiments revealed that TM-PAP was expressed in a
subset of small-diameter DRG neurons (Figure 1B), while the secretory isoform was expressed
at low-to-undetectable levels (Figure 1C). Importantly, TM-PAP is localized to the plasma
membrane and vesicular membranes, just like TMPase (Csillik and Knyihar-Csillik, 1986;
Quintero et al., 2007). We also found that PAP was expressed in human DRG using RT-PCR
and intron-spanning primers (data not shown), consistent with localization of TMPase to small-
diameter human DRG neurons (Silverman and Kruger, 1988a).
To directly test whether PAP had TMPase histochemical activity, we overexpressed mouse
TM-PAP in HEK 293 cells, then stained these cells using TMP histochemistry. Cells
transfected with TM-PAP were heavily stained when the plasma membrane was left intact
(Figure 2A), indicating that TM-PAP can dephosphorylate TMP extracellularly. TMPase
staining was even greater when the plasma membrane was permeabilized with detergent
(Figure S1H). In contrast, control cells transfected with empty vector were not stained (Figure
2B). Two additional phosphatases [soluble acid phosphatase 1 (ACP1) and placental alkaline
phosphatase] lacked TMPase activity (Figure S1).
DRG neurons express at least eight different acid phosphatase genes (M.J.Z, unpublished
expression profiling studies), any one of which could be TMPase. To determine if PAP was
the only enzyme in sensory neurons capable of dephosphorylating TMP, we analyzed DRG
and spinal cord tissues from PAPΔ3/Δ3 (henceforth referred to as PAP−/−) knockout mice
(Vihko et al., abstract from Proceedings of the AACR, 2005, 96th Annual Meeting, Anaheim,
CA). In these mice, deletion of exon 3 causes complete loss of secretory and transmembrane
PAP catalytic activity (Vihko et al., abstract from Proceedings of the AACR, 2005). Strikingly,
TMP histochemical staining of DRG neurons and axon terminals in spinal cord was abolished
in PAP−/− mice (Figure 2C–F). Absence of TMP staining in PAP−/− mice was not due to
developmental loss of DRG neurons, as wild-type and PAP−/− mice had equivalent numbers
of P2X3-expressing neurons relative to all NeuN+ neurons in lumbar ganglia (43.4 ± 1.9%
verses 42.4 ± 1.9% (s.e.m.); 1,500 NeuN+ neurons counted per genotype). P2X3 is an ATP-
gated ion channel that is co-localized with PAP (see below). Moreover, loss of TMPase staining
in the spinal cord was not due to loss of axon terminals in the dorsal horn (Figure S2). These
gain- and loss-of-function experiments conclusively prove that TMPase in small-diameter
DRG neurons is the transmembrane isoform of PAP.
In addition, by combining immunofluorescence and TMP histochemistry, we observed co-
localization between PAP and TMPase in DRG neurons (Figure S3A–C) and in axon terminals
in lamina II of the spinal cord (Figure S3D–F). This anti-PAP antibody did not stain DRG or
spinal cord sections from PAP−/− mice, confirming antibody specificity.
Lastly, upon finding that PAP was TMPase, we re-analyzed two published microarray data
sets that measured changes in gene expression in DRG following peripheral nerve injury
(Costigan et al., 2002; Davis-Taber, 2006). In both studies, PAP was one of the most heavily
downregulated genes. This is consistent with the fact that TMPase histochemical activity is
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greatly reduced in DRG and dorsal horn after peripheral nerve injury (Colmant, 1959; Csillik
and Knyihar-Csillik, 1986; Shields et al., 2003; Tenser, 1985; Tenser et al., 1991).
PAP is primarily expressed in nonpeptidergic DRG neurons
TMPase was previously localized to nonpeptidergic DRG neurons and a small number of
peptidergic neurons (Carr et al., 1990; Dalsgaard et al., 1984; Hunt and Mantyh, 2001; Nagy
and Hunt, 1982; Silverman and Kruger, 1988b). To show that PAP had a similar distribution
and to identify additional proteins that were co-localized with PAP, we performed double-label
immunofluorescence with our anti-PAP antibody and various sensory neuron markers. Cell
counts from confocal images revealed that virtually all nonpeptidergic DRG neurons, as
defined by the markers IB4, Mrgprd-EGFPf and P2X3, co-expressed PAP (Figure 3A–I, Table
S1). Moreover, PAP+ axons terminated in lamina II of spinal cord in association with
nonpeptidergic neuron markers (Figure S4A–F). In contrast, a smaller percentage (17.1%) of
peptidergic CGRP+ neurons (n=1364 cells counted) expressed PAP (Figure 3J–L, Table S1)
and there was minimal overlap between PAP+ and peptidergic (CGRP+) axon terminals in
spinal cord (Figure S4G–I). Lastly, 19.1 ± 1.3% of PAP+ neurons expressed the capsaicin and
noxious heat receptor TRPV1 (Figure 3M–O). Taken together, these confocal imaging studies
revealed that PAP was preferentially expressed in nonpeptidergic, presumably nociceptive,
DRG neurons.
Chronic pain-induced thermal hyperalgesia and mechanical allodynia is enhanced in PAP
knockout mice
PAP was generally thought to function only in the prostate (Ostrowski and Kuciel, 1994).
However, our expression data suggested that PAP might also function in nociceptive neurons.
To evaluate pain-related functions for PAP, we tested age-matched wild-type C57BL/6 and
PAP−/− male mice (backcrossed to C57BL/6 for 10 generations) using acute and chronic pain
behavioral assays. We found no significant differences between genotypes using a measure of
mechanical sensitivity (electronic von Frey) or several different measures of acute noxious
thermal sensitivity (Table S2). In contrast, PAP−/− mice showed significantly greater thermal
hyperalgesia and mechanical allodynia relative to wild-type mice in the Complete Freund’s
Adjuvant (CFA) model of chronic inflammatory pain (Figure 4A, B). In addition, PAP−/− mice
showed significantly greater thermal hyperalgesia in the spared nerve injury (SNI) model of
neuropathic pain (Figure 4C, D) (Shields et al., 2003).
PAP has potent and long-lasting anti-nociceptive properties
Since deletion of PAP enhanced sensitivity in two different models of chronic pain, we
hypothesized that excess PAP should have the opposite effect and reduce pain. To test this, we
took advantage of the fact that secretory PAP protein is commercially available and has the
same N-terminal catalytic region as TM-PAP (Figure 1A). We injected wild-type mice
intrathecally (i.t.) into the lumbar region of spinal cord with pure human (h)PAP protein (the
secretory isoform). Control mice were injected i.t. with an equivalent amount of heat-
denatured, and hence phosphatase-inactive, hPAP protein. In all cases, we determined that
hPAP was active or inactive using a sensitive fluorometric-based phosphatase assay (see
Experimental Procedures). We then measured noxious thermal and mechanical sensitivity
before (baseline, BL) and after hPAP injections (Figure 5A, B). Six hours after i.t. injection of
hPAP, paw withdrawal latency to a noxious thermal stimulus significantly increased relative
to controls and remained elevated for three days (Figure 5A). This anti-nociceptive effect was
dose-dependent (Figure S5) and required PAP catalytic activity (Figure 5A). Active hPAP did
not alter mechanical sensitivity (Figure 5B) nor did it cause paralysis or sedation. This long-
lasting anti-nociceptive effect was species-conserved as a single i.t. injection of bovine (b)PAP
also increased thermal withdrawal latency for two days but had no effect on mechanical
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sensitivity (Figure S6). Lastly, i.t. injection of an unrelated protein (bovine serum albumin) or
large quantities of a different secreted phosphatase (bovine alkaline phosphatase) did not alter
thermal or mechanical sensitivity (Figures S6, S7).
We next used the same behavioral assay to compare PAP anti-nociception to the commonly-
used opioid analgesic morphine. We found that PAP and morphine anti-nociception were
similar in magnitude following a single i.t. injection (40.8 ± 3.3% verses 62.2 ± 9.9% increase
above baseline at the highest doses, respectively) but PAP anti-nociception lasted much longer
than morphine (3 d verses 5 h at the highest doses, respectively. Figures S5, S8). Similarly,
Grant and colleagues found that the same high dose of morphine (50 µg, i.t., single injection)
lasted 4.6 ± 1.0 h in mice (Grant et al., 1995).
We next evaluated the extent to which hPAP affected hyperalgesia and allodynia in the CFA
model of inflammatory pain and the SNI model of neuropathic pain. For both chronic pain
assays, we used the uninjured paw as control. Strikingly, in both chronic pain models, a single
i.t. injection of active hPAP was anti-hyperalgesic and anti-allodynic in the inflamed/injured
paw (Figure 5C–F). As before, a single injection was effective for several days and phosphatase
activity was required for these anti-nociceptive effects.
Since PAP−/− mice showed enhanced hyperalgesia and allodynia in the CFA inflammatory
pain model (Figure 4A, B), we next tested whether hPAP could rescue these enhanced thermal
and mechanical phenotypes in PAP−/− mice. We found that i.t. injection of hPAP increased
thermal withdrawal latency in the control paw of PAP−/− mice to the same extent as wild-type
mice (Figure 6A, blue lines). This demonstrated that PAP−/− mice were competent to respond
to acute increases in PAP activity. Strikingly, injection of hPAP rescued the thermal and
mechanical inflammatory pain phenotype in the inflamed paw of PAP−/− mice (Figure 6A, B,
compare red lines where PAP was injected to black lines where inactive PAP was injected).
Importantly, these data also suggest that localized, spinal injection of hPAP can rescue the
behavioral deficit caused by deletion of PAP throughout the animal.
PAP suppresses pain by generating adenosine, a known analgesic in mammals
The anti-nociceptive effects of PAP require catalytic activity. This suggested PAP might
generate, via dephosphorylation, a molecule that regulates nociceptive neurotransmission in
the spinal cord. PAP and TMPase can dephosphorylate many different substrates (Dziembor-
Gryszkiewicz et al., 1978; Sanyal and Rustioni, 1974; Silverman and Kruger, 1988b; Vihko,
1978). We focused on AMP because dephosphorylation of AMP produces adenosine—a
molecule that inhibits nociceptive neurotransmission in spinal cord slices and has well-studied
analgesic properties in mammals (Li and Perl, 1994; Liu and Salter, 2005; Post, 1984;
Sawynok, 2006).
At the time we began our studies, there was no direct proof that PAP or TMPase could generate
adenosine from AMP. Instead, production of adenosine was inferred by measuring production
of inorganic phosphate (Vihko, 1978). To directly test whether PAP could generate adenosine
from AMP and other adenine nucleotides, we incubated PAP with 1 mM AMP, ADP or ATP
at pH 7.0 for 4 h. We then detected adenine nucleotides and adenosine using high performance
liquid chromatography (HPLC) and UV absorbance (Lazarowski et al., 2004). These studies
revealed that PAP can rapidly dephosphorylate AMP and, to a much lesser extent ADP, to
adenosine (Figure 7A, B). Importantly, no unexpected peaks were seen in the chromatograms
(Figure 7B, data not shown), ruling out the possibility that PAP had additional hydrolytic
activities towards nucleotides.
Next, we tested the extent to which PAP could dephosphorylate extracellular AMP in HEK
293 cells, DRG neurons and spinal cord using AMP enzyme histochemistry. HEK 293 cells
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transfected with TM-PAP were heavily stained whereas control cells were not (Figure 7C, D),
highlighting that TM-PAP dephosphorylates extracellular AMP and hence has ecto-5’-
nucleotidase activity. In addition, small-diameter DRG neurons from wild-type mice were
intensely stained while large-diameter neurons had weak granular cytoplasmic staining. In
contrast, only weak granular staining was present in DRG neurons from PAP−/− mice (Figure
7E, F). These data indicate that PAP is the predominant ecto-5’-nucleotidase on the soma of
small-diameter neurons. Lastly, AMP histochemical staining of axon terminals in lamina II
was reduced in PAP−/− relative to wild-type mice, but was not eliminated (Figure 7G, H). This
indicates that PAP is one of perhaps many enzymes in spinal cord with the ability to
dephosphorylate AMP to adenosine.
Adenosine mediates anti-nociception through Gi-coupled A1-adenosine receptors (A1Rs) (Lee
and Yaksh, 1996; Sawynok, 2006). To directly test whether A1Rs were required for PAP anti-
nociception, we next i.t. injected hPAP into wild-type C57BL/6 and A1-adenosine receptor
knockout mice (A1R−/−, Adora1−/−; backcrossed to C57BL/6 mice for 12 generations), then
measured noxious thermal and mechanical sensitivity (Hua et al., 2007; Johansson et al.,
2001). Strikingly, hPAP increased thermal paw withdrawal latency for three days in wild-type
mice but was without effect in A1R−/− mice (Figure 8A). Similarly, bPAP increased paw
withdrawal latency to the noxious thermal stimulus in wild-type mice but had no effect in
A1R−/− mice (Figure S9). As expected, hPAP did not affect mechanical sensitivity in uninjured
animals (Figure 8B).
We next tested wild-type and A1R−/− mice using the CFA chronic inflammatory pain model
and the SNI neuropathic pain model. Reproducing previous findings (Wu et al., 2005),
A1R−/− mice showed greater thermal hyperalgesia compared to wild-type mice after CFA
injection and after nerve injury (but before PAP injection; Figure 8C, E). Following i.t. injection
of hPAP, thermal and mechanical thresholds increased in the inflamed/injured paws of wild-
type mice but not in A1R−/− mice (Figure 8C–F). Likewise, the selective A1R antagonist 8-
cyclopentyl-1, 3-dipropylxanthine (CPX; 1 mg/kg, i.p.) transiently reversed the anti-
nociceptive effects of hPAP in control and inflamed hindpaws (Figure S10). Conversely,
injection (i.t.) of the selective A1R agonist N6-cyclopentyladenosine (CPA) into wild-type mice
produced dose-dependent increases in paw withdrawal latency to our thermal stimulus (Figure
S11), similar to i.t. hPAP. However unlike hPAP, CPA had short-term effects (lasting hours
not days) and CPA caused transient paralysis at the two highest doses. When taken together,
our results demonstrate that the anti-nociceptive effects of PAP are due to generation of
adenosine followed by activation of A1Rs. Moreover, our data demonstrate a novel in vivo
function for PAP as an ectonucleotidase.
DISCUSSION
For seventy years, PAP was thought to be a secreted protein found only in the prostate and was
used as a diagnostic marker for prostate cancer (Gutman and Gutman, 1938; Ostrowski and
Kuciel, 1994). Despite years of research, little was known about how PAP functioned in vivo
at a mechanistic level or which PAP substrate was most biologically relevant. In biochemical
assays, PAP can dephosphorylate diverse substrates, including β-glycerophosphate,
lysophosphatidic acid, phospho-amino acids and 5’-nucleotides (Dziembor-Gryszkiewicz et
al., 1978; Li et al., 1984; Porvari et al., 1994; Tanaka et al., 2004; Vihko, 1978).
In our efforts to solve an old and unanswered question in the pain field, we found that PAP
was expressed in nociceptive neurons, was anti-nociceptive and functioned as an
ectonucleotidase. Importantly, we found that the in vivo effects of PAP were eliminated by
deletion of one gene, the A1-adenosine receptor. This makes it unlikely that PAP suppresses
pain by generating any other molecules besides adenosine. Moreover, the in vivo effects of
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PAP on acute and chronic pain mimic the effects of i.t. adenosine and A1R agonists (Figure
S11) (Liu and Salter, 2005; SSawynok, 2006). Notably, both PAP and adenosine receptor
agonists have anti-allodynic and anti-hyperalgesic properties in animal models of
inflammatory and neuropathic pain, both have a long (>24 h) duration of action after a single
i.t. injection, and both lose their ability to suppress pain in A1R−/− mice and following injection
of A1R antagonists (Belfrage et al., 1999; Cui et al., 1997; Eisenach et al., 2002; Gomes et al.,
1999; Johansson et al., 2001; Lavand'homme and Eisenach, 1999; Lee and Yaksh, 1996;
Maione et al., 2007; Poon and Sawynok, 1998). In addition, both A1R−/− and PAP−/− mice
show enhanced thermal hyperalgesia, but not enhanced allodynia, in neuropathic pain models
(Figure 4C, D) (Wu et al., 2005). This shared modality-selective phenotype further supports
our conclusion that endogenous PAP works via A1R activation. Although our studies were
focused on nociceptive neurons, PAP is expressed in many other tissues (Quintero et al.,
2007) and thus could function as an ectonucleotidase throughout the body.
PAP has potent and long-lasting anti-nociceptive effects when compared to opioid
analgesics
Morphine and other opioids are powerful analgesics but have side effects that limit their long-
term use. We found that a single i.t. injection of hPAP (250 mU) produced an increase in paw
withdrawal latency of 40.8 ± 3.3% (relative to baseline; n=74 mice) in the Hargreaves test
(Figure S5C) and reproducibly lasted for three days (Figure 5, Figure 6, Figure 8, Figure S5A,
S10). Using the same behavioral test, we found that 1 µg and 10 µg of morphine produced an
increase in paw withdrawal latency of 24.9 ± 5.3% and 55.9 ± 13.7%, respectively, but lasted
1–4 h in mice (Figure S8). Similarly, others found that 1 µg and 10 µg of morphine (i.t., single
dose) produced an increase in paw withdrawal latency of 36% and 60%, respectively (Dirig
and Yaksh, 1995), that lasted hours in rats (Nishiyama et al., 2000; Zhang et al., 2005). Higher
doses of i.t. morphine cause motor impairment and death (Figure S8) (Dirig and Yaksh,
1995; Grant et al., 1995; Nishiyama et al., 2000). Although high doses of A1R agonists also
cause motor impairment (Figure S11) (Sawynok, 2006), we found no such side-effects at the
highest dose of PAP tested. These comparisons reveal that the magnitude of PAP and morphine
anti-nociception is similar; however, PAP anti-nociception lasts substantially longer. In fact,
using area under the curve (AUC) measurements that integrate magnitude of anti-nociception
over time, the 250 mU dose of hPAP is eight-times more effective than the highest dose of
morphine tested (Figures S5B, S8B). These long-lasting and A1R-dependent anti-nociceptive
effects of PAP are supported by previous studies showing that adenosine produces long-
duration (>24 h) analgesia in humans and rodents (Belfrage et al., 1999; Eisenach et al.,
2002; Lavand'homme and Eisenach, 1999). Lastly, we found that PAP anti-nociception could
be transiently inhibited with an A1R antagonist (Figure S10). This suggests that PAP is stable
in spinal cord following injection and is capable of producing adenosine for days. Likewise,
PAP has a very long (11.7 day) half-life in blood (Vihko et al., 1982).
PAP is the first molecularly-defined ectonucleotidase in nociceptive circuits
Nucleotides like ATP and ADP play key roles in pain mechanisms (Burnstock, 2007; Sawynok,
2006; Tozaki-Saitoh et al., 2008; Tsuda et al., 2005). Nucleotides are released extracellularly
by stimulated sensory neurons and activate purinergic P2X and P2Y receptors on neurons and
microglia. Activation of these receptors facilitates neurotransmission, sensitizes neurons and
causes pain. The excitatory effects of extracellular nucleotides can be terminated by several
membrane-bound and, in some cases, secreted ectonucleotidases. These ectonucleotidases
dephosphorylate extracellular ATP, ADP and AMP to adenosine (Zimmermann, 2006). While
ATP has excitatory effects and causes pain, adenosine has inhibitory effects and suppresses
pain (Nakagawa et al., 2007; Sawynok, 2006).
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One or more ectonucleotidases were known to exist in nociceptive circuits (Nagy and Daddona,
1985; Scott, 1967; Suran, 1974). Considering the key roles nucleotides and adenosine play in
pain mechanisms, it is surprising to note that none of these ectonucleotidases have been
molecularly identified. Using electrophysiological approaches, two groups found that
application of ATP, ADP or AMP inhibited postsynaptic neurons in the dorsal spinal cord
indirectly via metabolic conversion to adenosine (Li and Perl, 1995; Salter and Henry, 1985).
Likewise, Patterson and colleagues used indwelling microprobes and found that adenosine was
metabolically generated in vivo when the dorsal spinal cord was perfused with AMP (Patterson
et al., 2001). Dephosphorylation of AMP to adenosine was partially blocked by co-perfusion
with α,β-methylene-ADP (Patterson et al., 2001), an inhibitor of ecto-5’-nucleotidase (CD73).
This enzyme has not yet been molecularly-characterized in DRG neurons or spinal cord.
Our studies clearly show that PAP is expressed in small-diameter DRG neurons, that PAP
dephosphorylates AMP to adenosine in vitro, in heterologous cells, in DRG neurons and in
lamina II of the spinal cord, and that PAP anti-nociception requires A1Rs. To our knowledge,
none of the known ectonucleotidases (Zimmermann, 2006) have been studied at this level of
detail in nociceptive circuits. Collectively, this makes PAP the first molecularly-defined
ectonucleotidase in nociceptive circuits.
PAP is well-localized to modulate A1-adenosine receptors in spinal cord lamina II
Our data highlight a close functional relationship between PAP and A1Rs. This raises the
question of where PAP acts to modulate A1Rs and nociceptive behaviors. Within the spinal
cord, A1Rs are concentrated in lamina II, particularly on postsynaptic neurons that are in close
contact with IB4+ axon terminals, but not in close contact with CGRP+ axon terminals (Schulte
et al., 2003). A1Rs are also found presynaptically in small- to medium-diameter DRG neurons,
and possibly in the axon terminals of these neurons (based on accumulation of A1Rs proximal
to dorsal root ligature) (Schulte et al., 2003). In addition, A1R activation inhibits presynaptic
glutamate release primarily from unmyelinated terminals and inhibits postsynaptic neurons in
the substantia gelatinosa (lamina II) of spinal cord (Lao et al., 2001; Li and Perl, 1994; Patel
et al., 2001).
Considering that virtually all PAP+ neurons and axons are IB4+ (Table S1) and terminate in
lamina II (Figure S4), this makes PAP well-localized to generate extracellular adenosine and
modulate A1Rs on presynaptic terminals and on postsynaptic neurons in the IB4-binding region
of lamina II. In addition, PAP (TMPase) is enriched on the presynaptic membranes of DRG
neurons at the level of electron microscopy (Knyihar-Csillik et al., 1986) and has a broad pH
optimum (pH 3–8) (Van Etten, 1982), making PAP capable of generating adenosine locally at
synapses.
Further support for a central site of action comes from the fact that dephosphoryation of
extracellular AMP in lamina II is reduced in PAP−/− mice and PAP is anti-nociceptive when
injected intraspinally. Moreover, central injection of PAP can rescue behavioral deficits caused
by deletion of PAP throughout the animal (Figure 6).
Although our data clearly support a central mechanism of action, we cannot exclude the
possibility that PAP might also generate adenosine peripherally to mediate anti-nociception.
Peripheral administration of adenosine has long-lasting anti-nociceptive and analgesic effects
in rodents and humans, just like central administration (Hayashida et al., 2005; Sawynok,
2006). We detected PAP on axons in the dermis of the skin; however, our antibody was not
sensitive enough to detect PAP on axon terminals in epidermis (B.T-B. and M.J.Z,
unpublished). Moreover, others found that TMPase (PAP) accumulated proximal to a ligature
of the sural nerve, suggesting PAP is transported peripherally (McMahon and Moore, 1988).
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Physiological function of PAP throughout the body – insights from pain-sensing neurons
In prostate, PAP is thought to function as a tumor suppressor. Notably, prostate cancer cell
growth rate is reduced when secretory hPAP (referred to as “cellular” PAP by the authors) is
overexpressed (Lin et al., 1992; Meng and Lin, 1998; Veeramani et al., 2005). Conversely,
deletion of PAP (secreted and TM isoforms) in mice leads to prostate hyperplasia followed by
prostate cancer (Vihko et al., abstract from Proceedings of the AACR, 2005). The mechanism
by which PAP mediates growth suppression is, at present, unclear. Correlative data from Lin
and colleagues suggests secretory (“cellular”) PAP regulates growth directly by
dephosphorylating phosphotyrosine residues in the cytoplasmic tail of ErbB2 (Veeramani et
al., 2005). This direct mechanism seems unlikely, particularly since the cytoplasmic tail of
ErbB2 is not accessible to the active site of secretory PAP (which is located extracellularly
(Figure 1A) and in the lumen of vesicles). Instead, PAP could indirectly regulate proliferation
by generating adenosine.
In support of this, there are four adenosine receptor subtypes, with A1 and A3 coupled to
inhibitory Gi-proteins and A2a and A2b coupled to stimulatory Gq- and Gs-proteins (Jacobson
and Gao, 2006). PAP could differentially modulate intracellular signaling depending upon
which adenosine receptor subtypes are expressed by cells. Notably, A3-adenosine receptors
are found on prostate cancer cells and A3-agonists inhibit the growth of these cells (Fishman
et al., 2003).
Adenosine regulates many other physiological processes besides pain and cancer, including
anxiety, inflammation, blood pressure, pulmonary function and renal function (Jacobson and
Gao, 2006). TM-PAP is expressed throughout the body (Quintero et al., 2007). As such, TM-
PAP could regulate diverse physiological processes that are dependent on adenosine. Lastly,
our study overturns the long-held belief that PAP is a generic “acid phosphatase” by
discovering a specific in vivo function for PAP as an ectonucleotidase.
EXPERIMENTAL PROCEDURES
All procedures and behavioral experiments involving vertebrate animals were approved by
Institutional Animal Care and Use Committees at the University of North Carolina at Chapel
Hill and at the Universities of Oulu and Helsinki.
Molecular Biology
The full-length expression construct of PAP-transmembrane isoform (nt 64–1317 from
GenBank accession # NM_207668) was generated by RT-PCR amplification, using C57BL/
6 mouse trigeminal cDNA as template and Phusion polymerase. PCR products were cloned
into pcDNA3.1 and completely sequenced. Isoform-specific in situ hybridization probes of
PAP, secreted variant (nt 1544–2625 from GenBank accession # NM_019807) and PAP,
transmembrane variant (nt 1497–2577 from GenBank accession # NM_207668) were
generated by PCR amplification, using C57BL/6 mouse genomic DNA as template and
Phusion polymerase, then cloned into pBluescript-KS.
In situ hybridization was performed as described previously using digoxygenin-labeled
antisense and sense (control) riboprobes (Dong et al., 2001).
We confirmed that PAP was expressed in human DRG by performing RT-PCR with RNA from
human DRG (Clontech) and primers that spanned three introns (exon 6 primer: 5’
ctttcaggattacatggccagg and exon 9 primer: 5’ cgtcaagtggcaagaagcatag).
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Adult male mice, 6–12 weeks of age, were sacrificed by cervical dislocation, decapitation or
pentobarbital overdose. Lumbar spinal cord and DRG (L4–L6) were dissected, and then
postfixed for 8 h and 2 h, respectively. Tissues were cryoprotected in 20% sucrose, 0.1 M
phosphate buffer, pH 7.3 at 4°C for 24 hours, frozen in OCT, sectioned with a cryostat at 15–
20 µm, and mounted on Superfrost Plus slides. Slides were stored at −20°C. Free-floating
sections were sectioned at 30 µm and immediately stained.
Histology
Enzyme histochemistry was performed essentially as described by Shields et al., with
modifications suggested by Silverman and Kruger (Shields et al., 2003; Silverman and Kruger,
1988a). Briefly, cells or tissue sections were washed twice with 40 mM Trizma-Maleate (TM)
buffer, pH 5.6., then once with TM buffer containing 8% (w/v) sucrose. Samples were then
incubated at 37°C for 2 h in TM buffer containing 8% sucrose (w/v), 6 mM thiamine
monophosphate chloride or adenosine monophosphate (0.3 mM for tissue sections, 6 mM for
HEK 293 cells), and 2.4 mM lead nitrate. Lead nitrate must be made fresh immediately prior
to use. To reduce non-specific background staining, samples were washed once with 2% acetic
acid for one minute. Samples were then washed three times with TM buffer, developed for 10
seconds with 1% sodium sulfide, washed several times with PBS, pH 7.4, and mounted in Gel/
Mount (Biomeda). When assaying HEK 293 cells using TMP or AMP histochemistry, we
stained duplicate samples with and without 0.1% Triton X-100 in the initial TM wash. Images
were acquired using a Zeiss Axioskop and Olympus DP-71 camera.
Immunofluorescence was performed using antibodies and procedures as previously described
(Zylka et al., 2005). Additional antibodies included: 1:250 mouse anti-NeuN (MAB377,
Chemicon), 1:300 guinea pig anti-P2X3 (GP10108, Neuromics), 1:1000 goat anti-VR1
(sc-12498, Santa Cruz) and 1:1000 rabbit anti-human PAP (Biomeda). We found it was
necessary to amplify the anti-PAP antibody signal by using secondary antibodies conjugated
to biotin, then using either 1:250 Streptavidin-Cy3 (Jackson) or the Tyramide Signal
Amplification kit (New England Nuclear, following manufacturers protocol). Images were
obtained using a Leica TCS-NT confocal microscope.
Injections and Drugs
For intrathecal drug delivery, 5 µL was injected into unanesthetized mice using the direct
lumbar puncture method (Fairbanks, 2003). Human PAP (Sigma, P1774, 100 U/mL) was
dialyzed against 0.9% saline using Slide-A-Lyzer Mini dialysis units (Pierce, 69576) for 4
hours at 4°C. After dialysis, samples were diluted in 0.9% saline to a final concentration of 1.3
mg/mL (50 U/mL) and stored at −80°C. hPAP was heat-inactivated by incubating at 65°C for
40 min. Bovine prostatic acid phosphatase (bPAP, Sigma, P6409) was dissolved (aided by
sonication) in 0.9% saline to a final concentration of 30 mg/mL (0.3 U/mL). Enzyme activity
was quantified using the EnzChek Phosphatase Assay Kit (Invitrogen, E12020) following the
manufacturer’s protocol. Bovine serum albumin (BSA, Sigma, A3912) was dissolved in 0.9%
saline to a final concentration of 1.3 mg/mL. Recombinant bovine alkaline phosphatase was
purchased from Sigma (P8361, expressed in Pichia pastoris, >4000 U/mg protein). Morphine
sulfate (Sigma, M8777) and N6-cyclopentyladenosine (Sigma, C8031; 10 mM stock in
dimethylsulfoxide (DMSO)) were diluted into 0.9% saline. 8-cyclopentyl-1, 3-
dipropylxanthine (C101, Sigma) was dissolved in 0.9% saline containing 5% DMSO, 1.25%
1 M NaOH and injected i.p.
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PAP−/− and A1R−/− mice were backcrossed to C57BL/6 mice (Jackson) for 10 and 12
generations, respectively. Isogenic wild-type mice were then derived from the PAP−/− line and
used as wild-type controls. C57BL/6 male mice were purchased from Jackson Laboratories for
all behavioral experiments involving PAP protein injections. Unless indicated otherwise, male
mice, 2–4 months old, were used for all behavioral experiments. All mice were acclimated to
the testing room, equipment and experimenter for one to three days before behavioral testing.
The experimenter was blind to genotype and drug treatment during behavioral testing.
Thermal sensitivity was measured by heating one hindpaw with a Plantar Test apparatus (IITC)
following the Hargreaves method (Hargreaves et al., 1988). The radiant heat source intensity
was calibrated so that a paw withdrawal reflex was evoked in ~10 s., on average, in wild-type
C57BL/6 mice. Cutoff time was 20 s. One measurement was taken from each paw per day to
determine paw withdrawal latency (with the exception of our morphine and CPA dose-response
experiments which required multiple measurements per day). To perform the tail immersion
assay, mice were gently restrained in a towel and the distal one-third of the tail was immersed
in 46.5°C or 49°C water. Latency to withdrawal the tail was measured once per mouse. For
the hot plate test, mice were placed on a metal surface heated at 52°C and latency to jump, lick
paws or shake paws was measured. Mechanical sensitivity was measured using semi-flexible
tips attached to an Electronic von Frey apparatus (IITC) as described elsewhere (Cunha et al.,
2004; Inoue et al., 2004). Three measurements were taken from each paw (separated at 10 min
intervals) then averaged to determine paw withdrawal threshold in grams.
To induce inflammatory pain, 20 µL Complete Freunds Adjuvant (CFA, from Sigma or MP
Biomedicals) was injected into one hindpaw, centrally beneath glabrous skin, with a 30G
needle. The spared nerve injury (SNI) model of neuropathic pain was performed as described
(Shields et al., 2003).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DRG neurons express the transmembrane isoform of PAP
(A) Secreted and transmembrane isoforms of PAP. Both isoforms have identical N-terminal
regions, including the signal peptide (SP) and extracellular catalytic acid phosphatase domain.
Alternative splicing at the last intron-exon junction (arrow) results in the inclusion or exclusion
of a transmembrane (TM) domain. (B, C) In situ hybridization of mouse lumbar DRG with
riboprobes complimentary to the unique 3’ untranslated regions of (B) the transmembrane
isoform or (C) the secreted isoform. Scale bar: 50 µm in B, C.
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Figure 2. PAP dephosphorylates TMP in HEK 293 cells and nociceptive circuits
(A) HEK 293 cells were transfected with a mouse TM-PAP expression construct or (B) with
empty pcDNA3.1 vector and then stained using TMP histochemistry. The plasma membrane
was not permeabilized so that extracellular phosphatase activity could be assayed. (C–D)
Lumbar DRG and (E–F) spinal cord from wild-type and PAP−/− adult mice stained using TMP
histochemistry. Identical results were obtained from fourteen additional mice of each genotype.
TMP (6 mM) was used as substrate and buffer pH was 5.6 in all panels. Scale bar: 50 µm in
A–D; 500 µm in E, F.
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Figure 3. PAP is primarily expressed in nonpeptidergic neurons
(A–O) Mouse L4–L6 DRG neurons were stained with antibodies against various sensory
neuron markers (green) and with antibodies against PAP (red). Tissue from adult
MrgprdΔEGFPf mice was used to identify Mrgprd-expressing neurons. Arrowheads mark
examples of double-labeled cells. Images were acquired by confocal microscopy. Scale bar
(bottom right panel): 50 µm for all panels.
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Figure 4. PAP−/− mice show enhanced nociceptive responses following inflammation and nerve
injury
(A, B) CFA inflammatory pain model. Wild-type and PAP−/− mice were tested for (A) thermal
sensitivity using a radiant heat source and (B) mechanical sensitivity using an electronic von
Frey semi-flexible tip before (baseline, BL) and following injection of CFA (CFA-arrow) into
one hindpaw. The non-inflamed hindpaw served as control. (C, D) SNI neuropathic pain model.
The sural and common peroneal branches of the sciatic nerve were ligated then transected
(Injure-arrow). Injured and non-injured (control) hindpaws were tested for (C) thermal and (D)
mechanical sensitivity. (A–D) Paired t-tests were used to compare responses at each time point
between wild-type (n=10) and PAP−/− mice (n=10); same paw comparisons. * P < 0.05; **
P < 0.005; *** P < 0.0005. All data are presented as means ± s.e.m.
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Figure 5. hPAP protein has long-lasting anti-nociceptive effects when injected intraspinally
(A, B) Wild-type mice were tested for (A) thermal and (B) mechanical sensitivity before
(baseline, BL) and following i.t. injection of active or inactive hPAP (hPAP-arrow). (C, D)
CFA inflammatory pain model. CFA was injected into one hindpaw (CFA-arrow). Active or
inactive hPAP was i.t. injected one day later (hPAP-arrow). Inflamed and non-inflamed
(control) hindpaws were tested for (C) thermal and (D) mechanical sensitivity. (E, F) SNI
neuropathic pain model. The sural and common peroneal branches of the sciatic nerve were
ligated then transected (Injure-arrow). Active or inactive hPAP was i.t. injected six days later
(hPAP-arrow). Injured and non-injured (control) hindpaws were tested for (E) thermal and (F)
mechanical sensitivity. (A–F) 250 mU hPAP injected per mouse. Paired t-tests were used to
Zylka et al. Page 20













compare responses at each time point between mice injected with active hPAP (n=10 mice per
experiment) to mice injected with heat-inactivated hPAP (n=10 mice per experiment); same
paw comparisons. * P < 0.05; ** P < 0.005; *** P < 0.0005. All data are presented as means
± s.e.m.
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Figure 6. Intraspinal PAP has anti-nociceptive effects in PAP−/− mice and rescues the chronic
inflammatory pain behavioral phenotype in PAP−/− mice
Wild-type and PAP−/− mice were tested for (A) thermal sensitivity and (B) mechanical
sensitivity before (baseline, BL) and following injection of CFA (CFA-arrow) into one
hindpaw. The non-inflamed hindpaw served as control. One day later, half of the wild-type
and PAP−/− mice were injected with active hPAP (hPAP-arrow; 250 mU, i.t.; red and blue
lines) while the other half were injected with inactive hPAP (black lines). Note: Data from
these inactive hPAP injected mice were presented in Figure 4A, B. Paired t-tests were used to
compare responses at each time point between wild-type (n=10/group) and PAP−/− mice
(n=10/group); same paw comparisons (n=40 mice were used for this experiment). * P < 0.05;
** P < 0.005; *** P < 0.0005. All data are presented as means ± s.e.m.
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Figure 7. PAP has ecto-5’-nucleotidase activity as revealed by dephosphorylation of AMP to
adenosine in vitro, in cells and in nociceptive circuits
(A) hPAP (2.5 U/mL) was incubated with 1 mM AMP, ADP, or ATP. Reactions (n=3 per time
point) were stopped by heat denaturation at the indicated times. Conversion of nucleotides to
adenosine was measured by HPLC. (B) HPLC chromatogram before (t=0) and after (t=240
min) incubation of 1 mM AMP with hPAP. Peaks corresponding to adenosine (ado) and AMP
are indicated. Arbitrary units (a.u.). (C) HEK 293 cells were transfected with a mouse TM-
PAP expression construct or (D) with empty pcDNA3.1 vector and then stained using AMP
histochemistry. The plasma membrane was not permeabilized so that extracellular phosphatase
activity could be assayed. (E–F) Lumbar DRG and (G–H) spinal cord from wild-type and
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PAP−/− adult mice stained using AMP histochemistry. Motor neurons in the ventral horn of
wild type and PAP−/− spinal cord were also stained. Identical results were obtained from five
additional mice of each genotype. AMP (6 mM in C, D and 0.3 mM in E–H) was used as
substrate and buffer pH was 5.6. Scale bar: 50 µm in C–F; 500 µm in G, H.
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Figure 8. PAP requires A1-adenosine receptors for anti-nociception
(A, B) Wild-type and A1R−/− mice were tested for (A) thermal and (B) mechanical sensitivity
before (baseline, BL) and following i.t. injection of hPAP (hPAP-arrow). (C, D) CFA was
injected into one hindpaw (CFA-arrow) of wild-type and A1R−/− mice. Active or inactive hPAP
was i.t. injected one day later (hPAP-arrow). Inflamed and non-inflamed (control) hindpaws
were tested for (C) thermal and (D) mechanical sensitivity. (E, F) The SNI model was used to
induce neuropathic pain (Injure-arrow) in wild-type and A1R−/− mice. Active or inactive hPAP
was i.t. injected four days later (hPAP-arrow). Injured and non-injured (control) hindpaws were
tested for (E) thermal and (F) mechanical sensitivity. For all experiments, 250 mU hPAP was
injected per mouse. T-tests were used to compare responses at each time point between wild-
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type (n=10) and A1R−/− mice (n=9); same paw comparisons. * P < 0.05; ** P < 0.005; ***
P < 0.0005. All data are presented as means ± s.e.m.
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